Search

Your search keyword '"Bastiaannet, Esther"' showing total 728 results
Start Over Author "Bastiaannet, Esther"
728 results on '"Bastiaannet, Esther"'

101. Should watch and wait be offered to rectal cancer patients younger than 50 years after a clinical complete response?

Author

Bahadoer, Renu, primary, Peeters, Koen, additional, Beets, Geerard, additional, Figueiredo, Nuno, additional, Bastiaannet, Esther, additional, Vahrmeijer, Alexander, additional, Temmink, Sofieke, additional, Meershoek-Klein Kranenbarg, Elma, additional, Roodvoets, Annet, additional, Habr-Gama, Angelita, additional, Perez, Rodrigo, additional, van de Velde, Cornelis, additional, and Hilling, Denise, additional

Published
2022
Full Text
View/download PDF

102. Predicting postoperative complications and their impact on quality of life and functional status in older patients with breast cancer

Author

Lemij, Annelieke, primary, van der Plas-Krijgsman, Willeke, additional, Bastiaannet, Esther, additional, Merkus, Jos, additional, van Dalen, Thijs, additional, Vulink, Annelie, additional, van Gerven, Leander, additional, Guicherit, Onno, additional, Linthorst-Niers, Eugenie, additional, Lans, Titia, additional, van der Pol, Carmen, additional, Wyld, Lynda, additional, Morgan, Jenna, additional, Portielje, Johanneke, additional, de Glas, Nienke, additional, and Liefers, Gerrit Jan, additional

Published
2022
Full Text
View/download PDF

107. Response

Author

van de Water, Willemien, Kiderlen, Mandy, Bastiaannet, Esther, Westendorp, Rudi G.J., van de Velde, C. J. H., de Craen, Anton j. M., and Liefers, Gerrit-Jan

Published
2014
Full Text
View/download PDF

108. Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study

Author

van der Plas-Krijgsman, Willeke G, primary, Giardiello, Daniele, additional, Putter, Hein, additional, Steyerberg, Ewout W, additional, Bastiaannet, Esther, additional, Stiggelbout, Anne M, additional, Mooijaart, Simon P, additional, Kroep, Judith R, additional, Portielje, Johanneke E A, additional, Liefers, Gerrit-Jan, additional, and de Glas, Nienke A, additional

Published
2021
Full Text
View/download PDF

109. Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4

Author

Ouahoud, Sarah, primary, Jacobs, Rutger J., additional, Kodach, Ludmilla L., additional, Voorneveld, Philip W., additional, Hawinkels, Lukas J. A. C., additional, Weil, Nikki L., additional, van Vliet, Britt, additional, Herings, Ron M., additional, van der Burg, Lennart R. A., additional, van Wezel, Tom, additional, Morreau, Hans, additional, Slingerland, Marije, additional, Bastiaannet, Esther, additional, Putter, Hein, additional, and Hardwick, James C. H., additional

Published
2021
Full Text
View/download PDF

112. A Prediction Model for Severe Complications after Elective Colorectal Cancer Surgery in Patients of 70 Years and Older

Author

Souwer, Esteban T. D., primary, Bastiaannet, Esther, additional, Steyerberg, Ewout W., additional, Dekker, Jan Willem T., additional, Steup, Willem H., additional, Hamaker, Marije M., additional, Sonneveld, Dirk J. A., additional, Burghgraef, Thijs A., additional, van den Bos, Frederiek, additional, and Portielje, Johanna E. A., additional

Published
2021
Full Text
View/download PDF

113. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A., primary, Bastiaannet, Esther, additional, van den Bos, Frederiek, additional, Mooijaart, Simon P., additional, van der Veldt, Astrid A. M., additional, Suijkerbuijk, Karlijn P. M., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan-Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Jalving, Hilde, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, ten Tije, Albert J., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Portielje, Johanneke E. A., additional, and Kapiteijn, Ellen W., additional

Published
2021
Full Text
View/download PDF

115. sj-pdf-1-tam-10.1177_17588359211027837 – Supplemental material for Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care

Author

Huang, Lei, Jansen, Lina, Verhoeven, Rob H.A., Ruurda, Jelle P., Van Eycken, Liesbet, De Schutter, Harlinde, Johansson, Jan, Lindblad, Mats, Johannesen, Tom B., Zadnik, Vesna, Žagar, Tina, Mägi, Margit, Lagarde, Sjoerd M., Bastiaannet, Esther, van de Velde, Cornelis J.H., Schrotz-King, Petra, and Brenner, Hermann

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-tam-10.1177_17588359211027837 for Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care by Lei Huang, Lina Jansen, Rob H.A. Verhoeven, Jelle P. Ruurda, Liesbet Van Eycken, Harlinde De Schutter, Jan Johansson, Mats Lindblad, Tom B. Johannesen, Vesna Zadnik, Tina Žagar, Margit Mägi, Sjoerd M. Lagarde, Esther Bastiaannet, Cornelis J.H. van de Velde, Petra Schrotz-King and Hermann Brenner in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

116. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

Author

Jochems, A., Bastiaannet, Esther, Aarts, M.J., Akkooi, Alexander C.J. van, Berkmortel, F.W. van den, Boers-Sonderen, M.J., Hoeven, J.J.M. van der, Kapiteijn, E., Wouters, M.W., Jochems, A., Bastiaannet, Esther, Aarts, M.J., Akkooi, Alexander C.J. van, Berkmortel, F.W. van den, Boers-Sonderen, M.J., Hoeven, J.J.M. van der, Kapiteijn, E., and Wouters, M.W.

Abstract

Item does not contain fulltext

Published
2021

117. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

Glas, Nienke A. de, Bastiaannet, Esther, Bos, Frederiek van den, Mooijaart, Simon P., Veldt, A.A.M. van der, Suijkerbuijk, K.P., Boers-Sonderen, M.J., Portielje, Johanneke E.A., Kapiteijn, E., Glas, Nienke A. de, Bastiaannet, Esther, Bos, Frederiek van den, Mooijaart, Simon P., Veldt, A.A.M. van der, Suijkerbuijk, K.P., Boers-Sonderen, M.J., Portielje, Johanneke E.A., and Kapiteijn, E.

Abstract

Contains fulltext : 235097.pdf (Publisher’s version ) (Open Access)

Published
2021

118. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, Kapiteijn, Ellen W, de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, and Kapiteijn, Ellen W

Abstract

BACKGROUND: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and outcomes of "real-world" older patients with metastatic melanoma and to identify predictors of outcome.METHODS: We included patients aged ≥65 years with metastatic melanoma from the Dutch Melanoma Treatment Registry. We described the reasons for hospital admissions and treatment discontinuation. Additionally, we assessed predictors of toxicity and response using logistic regression models and survival using Cox regression models.RESULTS: We included 2216 patients. Grade ≥3 toxicity was not associated with age, comorbidities or WHO status. Patients aged ≥75 discontinued treatment due to toxicity more often, resulting in fewer treatment cycles. Response rates were similar to previous trials (40.3% and 43.6% in patients aged 65-75 and ≥75, respectively, for anti-PD1 treatment) and did not decrease with age or comorbidity. Melanoma-specific survival was not affected by age or comorbidity.CONCLUSION: Response rates and toxicity outcomes of checkpoint inhibitors did not change with increasing age or comorbidity. However, the impact of grade I-II toxicity on quality of life deserves further study as older patients discontinue treatment more frequently.

Published
2021

119. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US:a population-based study calling for further standardization of care

Author

Huang, Lei, Jansen, Lina, Verhoeven, Rob H.A., Ruurda, Jelle P., Van Eycken, Liesbet, De Schutter, Harlinde, Johansson, Jan, Lindblad, Mats, Johannesen, Tom B., Zadnik, Vesna, Žagar, Tina, Mägi, Margit, Lagarde, Sjoerd M., Bastiaannet, Esther, van de Velde, Cornelis J.H., Schrotz-King, Petra, Brenner, Hermann, Huang, Lei, Jansen, Lina, Verhoeven, Rob H.A., Ruurda, Jelle P., Van Eycken, Liesbet, De Schutter, Harlinde, Johansson, Jan, Lindblad, Mats, Johannesen, Tom B., Zadnik, Vesna, Žagar, Tina, Mägi, Margit, Lagarde, Sjoerd M., Bastiaannet, Esther, van de Velde, Cornelis J.H., Schrotz-King, Petra, and Brenner, Hermann

Abstract

Aims: The role of resection remains debated in cases of metastatic gastric carcinoma (mGC). Some mGCs are technically resectable. At the population level, the real-world application of resection for mGC remains largely unclear in most Western countries. This large, population-based international investigation aimed to reveal the resection patterns and trends for mGC and the treatment-associated factors in Europe and the US. Methods: Data on cases with microscopically-confirmed primary invasive stomach carcinoma with distant metastasis were obtained from the nationwide cancer registries of the Netherlands, Belgium, Norway, Sweden, Estonia, and Slovenia and the US Surveillance, Epidemiology, and End Results-18 database. We calculated age-standardized rates of primary cancer-directed resection and assessed resection trends using linear regression. We investigated associations of treatment with patient and cancer factors using multivariable-adjusted log-binomial regression. Results: Among 133,321 patients with gastric cancer, overall, 40,215 cases with mGC diagnosed between 2003–2017 were investigated. Age-standardized resection rates significantly declined over time in the US, Belgium, Sweden, and Norway (by 5–14%). Resection rates greatly differed from 5% to 16% in 2013–2014. Cases with older ages, cardia tumors, or tumors involving adjacent structures were significantly less often operated across most countries. Sex was not significantly associated with resection. Across countries the association patterns and strengths differed largely. With multivariable adjustment, resection rates decreased significantly in all countries except Slovenia and Estonia (prevalence ratio per year = 0.90–0.98), and the decreasing trends were consistently observed in various stratifications by age and location. Conclusion: In Europe and the US, resection patterns and trends largely varied across countries for mGCs, which were mostly less often resected in the early 21st century. Variou

Published
2021

120. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST):A large, retrospective multicenter European study

Author

Mohammadi, Mahmoud, IJzerman, Nikki S, Hohenberger, Peter, Rutkowski, Piotr, Jones, Robin L, Martin-Broto, Javier, Gronchi, Alessandro, Schöffski, Patrick, Vassos, Nikolaos, Farag, Sheima, Baia, Marco, Oosten, Astrid W, Steeghs, Neeltje, Desar, Ingrid M E, Reyners, An K L, van Sandick, J W, Bastiaannet, Esther, Gelderblom, Hans, Schrage, Yvonne, Mohammadi, Mahmoud, IJzerman, Nikki S, Hohenberger, Peter, Rutkowski, Piotr, Jones, Robin L, Martin-Broto, Javier, Gronchi, Alessandro, Schöffski, Patrick, Vassos, Nikolaos, Farag, Sheima, Baia, Marco, Oosten, Astrid W, Steeghs, Neeltje, Desar, Ingrid M E, Reyners, An K L, van Sandick, J W, Bastiaannet, Esther, Gelderblom, Hans, and Schrage, Yvonne

Abstract

BACKGROUND: Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited.METHODS: Clinicopathological features and outcomes in patients with primary oesophageal GIST from seven European countries were collected retrospectively.RESULTS: Eighty-three patients were identified, and median follow up was 55.0 months. At diagnosis, 59.0% had localized disease, 25.3% locally advanced and 13.3% synchronous metastasis. A biopsy (Fine Needle aspiration n = 29, histological biopsy n = 31) was performed in 60 (72.3%) patients. The mitotic count was low (<5 mitoses/50 High Power Fields (HPF)) in 24 patients and high (≥5 mitoses/50 HPF) in 27 patients. Fifty-one (61.4%) patients underwent surgical or endoscopic resection. The most common reasons to not perform an immediate resection (n = 31) were; unresectable or metastasized GIST, performance status/comorbidity, patient refusal or ongoing neo-adjuvant therapy. The type of resections were enucleation (n = 11), segmental resection (n = 6) and oesophagectomy with gastric conduit reconstruction (n = 33), with median tumour size of 3.3 cm, 4.5 cm and 7.7 cm, respectively. In patients treated with enucleation 18.2% developed recurrent disease. The recurrence rate in patients treated with segmental resection was 16.7% and in patients undergoing oesophagectomy with gastric conduit reconstruction 36.4%. Larger tumours (≥4.0 cm) and high (>5/5hpf) mitotic count were associated with worse disease free survival.CONCLUSION: Based on the current study, enucleation can be recommended for oesophageal GIST smaller than 4 cm, while oesophagectomy should be preserved for larger tumours. Patients with larger tumours (>4 cm) and/or high mitotic count should be treated with adjuvant therapy.

Published
2021

121. Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands:a population-based study

Author

van der Plas-Krijgsman, Willeke G., Giardiello, Daniele, Putter, Hein, Steyerberg, Ewout W., Bastiaannet, Esther, Stiggelbout, Anne M., Mooijaart, Simon P., Kroep, Judith R., Portielje, Johanneke E.A., Liefers, Gerrit Jan, de Glas, Nienke A., van der Plas-Krijgsman, Willeke G., Giardiello, Daniele, Putter, Hein, Steyerberg, Ewout W., Bastiaannet, Esther, Stiggelbout, Anne M., Mooijaart, Simon P., Kroep, Judith R., Portielje, Johanneke E.A., Liefers, Gerrit Jan, and de Glas, Nienke A.

Abstract

Background: Current prediction tools for breast cancer outcomes are not tailored to the older patient, in whom competing risk strongly influences treatment effects. We aimed to develop and validate a prediction tool for 5-year recurrence, overall mortality, and other-cause mortality for older patients (aged ≥65 years) with early invasive breast cancer and to estimate individualised expected benefits of adjuvant systemic treatment. Methods: We selected surgically treated patients with early invasive breast cancer (stage I–III) aged 65 years or older from the population-based FOCUS cohort in the Netherlands. We developed prediction models for 5-year recurrence, overall mortality, and other-cause mortality using cause-specific Cox proportional hazard models. External validation was performed in a Dutch Cancer registry cohort. Performance was evaluated with discrimination accuracy and calibration plots. Findings: We included 2744 female patients in the development cohort and 13631 female patients in the validation cohort. Median age was 74·8 years (range 65–98) in the development cohort and 76·0 years (70–101) in the validation cohort. 5-year follow-up was complete for more than 99% of all patients. We observed 343 and 1462 recurrences, and 831 and 3594 deaths, of which 586 and 2565 were without recurrence, in the development and validation cohort, respectively. The area under the receiver-operating-characteristic curve at 5 years in the external dataset was 0·76 (95% CI 0·75–0·76) for overall mortality, 0·76 (0·76–0·77) for recurrence, and 0·75 (0·74–0·75) for other-cause mortality. Interpretation: The PORTRET tool can accurately predict 5-year recurrence, overall mortality, and other-cause mortality in older patients with breast cancer. The tool can support shared decision making, especially since it provides individualised estimated benefits of adjuvant treatment. Funding: Dutch Cancer Foundation and ZonMw.

Published
2021

122. Outcomes for systemic therapy in older patients with metastatic melanoma:Results from the Dutch Melanoma Treatment Registry

Author

Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Glas, Nienke G., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., van der Hoeven, Jacobus J.M., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, van Zeijl, Michiel C.T., Kapiteijn, Ellen, Wouters, Michel W.J.M., Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Glas, Nienke G., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., van der Hoeven, Jacobus J.M., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, van Zeijl, Michiel C.T., Kapiteijn, Ellen, and Wouters, Michel W.J.M.

Abstract

Background: The incidence of metastatic melanoma is increasing in all ages. Multiple trials with targeted drugs and immune checkpoint inhibitors showed improved survival in metastatic melanoma. However, patients aged ≥75 years are often under-represented in clinical trials, therefore raising questions on safety and efficacy of treatment. Patients and methods: We analyzed a real-world cohort of 3054 patients with metastatic melanoma stratified for age (≤65 years, 66–74 years and ≥ 75 years), and BRAF status, providing data on treatment strategies, toxicity, and survival. Kaplan Meier curves and Cox Proportional Hazard Models were used to present overall survival (OS) and Melanoma Specific Survival (MSS). Results: Overall, 52.2% of patients were ≤ 65 years and 18.4% of patients ≥75 years. BRAF mutated tumors were found less often in patients ≥75 years: 34.5% versus 65% in patients ≤65 years. Patients ≥75 years received systemic therapy less frequently compared to their younger counterparts independent of the BRAF status. When receiving treatment, no statistical significant difference in grade 3 or 4 toxicity was observed. Three year Overall Survival rate was 13.7% (9.1–19.3) in patients ≥75 years versus 26.7% (23.1–30.4) in patients ≤65 years, with a Hazard Ratio (HR) of 1.71 (95%CI 1.50–1.95), p < 0.001. Three year Melanoma Specific Survival was 30.4% (22.0–39.2) versus 34.0% (29.7–38.2), HR 1.26 (95% CI 1.07–1.49), p = 0.005 with an adjusted HR of 1.21 (1.00–1.47), p = 0.049. Conclusion: Patients with metastatic melanoma ≥75 years are less frequently treated, but when treated there is no statistical significant increase in toxicity and only a borderline statistical significant difference in Melanoma Specific Survival was seen, compared to younger patients.

Published
2021

123. Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors†

Author

MS Medische Oncologie, Infection & Immunity, Cancer, de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A.M., Suijkerbuijk, Karlijn P.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., Ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Portielje, Johanneke E.A., Kapiteijn, Ellen W., MS Medische Oncologie, Infection & Immunity, Cancer, de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A.M., Suijkerbuijk, Karlijn P.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., Ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Portielje, Johanneke E.A., and Kapiteijn, Ellen W.

Published
2021

124. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Glas, Nienke G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, van der Hoeven, Jacobus J M, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Kapiteijn, Ellen, Wouters, Michel W J M, MS Medische Oncologie, Infection & Immunity, Cancer, Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Glas, Nienke G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, van der Hoeven, Jacobus J M, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Kapiteijn, Ellen, and Wouters, Michel W J M

Published
2021

131. Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.

Author

De Glas, Nienke A, primary, Bastiaannet, Esther, additional, van den Bos, Frederiek, additional, Mooijaart, Simon, additional, Van Der Veldt, Astrid Aplonia Maria, additional, Suijkerbuijk, Karijn, additional, Aarts, Maureen J.B., additional, van den Berkmortel, Franchette, additional, Blank, Christian U., additional, Boers-Sonderen, Marye, additional, van den Eertwegh, Alfonsus Johannes Maria, additional, de Groot, Jan Willem, additional, Hospers, Geke, additional, Haanen, John B. A. G., additional, Piersma, Djura, additional, Van Rijn, Rozemarijn, additional, Ten Tije, A. J., additional, Wouters, Michel W.J.M., additional, Portielje, Johanna Elisabeth A., additional, and Kapiteijn, Ellen, additional

Published
2021
Full Text
View/download PDF

136. Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma

Author

Kooij, Monique K. van der, Wetzels, Marjolein J.A.L., Aarts, Maureen J.B., Berkmortel, Franchette W.P.J. van den, Blank, Christian U., Boers-Sonderen, Marye J., Dierselhuis, Miranda P., Groot, Jan Willem B. de, Hospers, Geke A.P., Piersma, Djura, Rijn, Rozemarijn S. van, Suijkerbuijk, Karijn P.M., Tije, Albert J. ten, Veldt, Astrid A.M. van der, Vreugdenhil, Gerard, Wouters, Michel W.J.M., Haanen, John B.A.G., Eertwegh, Alfonsus J.M. van den, Bastiaannet, Esther, and Kapiteijn, Ellen

Subjects
advanced melanoma, young adults, BRAF mutation, AYA, prospective nation-wide data, clinical audit, outcome research, adolescents, targeted therapy, neoplasms, checkpoint inhibitors, humanities
Abstract

Cutaneous melanoma is a common type of cancer in Adolescents and Young Adults (AYAs, 15&ndash, 39 years of age). However, AYAs are underrepresented in clinical trials investigating new therapies and the outcomes from these therapies for AYAs are therefore unclear. Using prospectively collected nation-wide data from the Dutch Melanoma Treatment Registry (DMTR), we compared baseline characteristics, mutational profiles, treatment strategies, grade 3&ndash, 4 adverse events (AEs), responses and outcomes in AYAs (n = 210) and older adults (n = 3775) who were diagnosed with advanced melanoma between July 2013 and July 2018. Compared to older adults, AYAs were more frequently female (51% versus 40%, p = 0.001), and had a better Eastern Cooperative Oncology Group performance status (ECOG 0 in 54% versus 45%, p = 0.004). BRAF and NRAS mutations were age dependent, with more BRAF V600 mutations in AYAs (68% versus 46%) and more NRAS mutations in older adults (13% versus 21%), p &lt, 0.001. This finding translated in distinct first-line treatment patterns, where AYAs received more initial targeted therapy. Overall, grade 3&ndash, 4 AE percentages following first-line systemic treatment were similar for AYAs and older adults, anti-PD-1 (7% versus 14%, p = 0.25), anti-CTLA-4 (16% versus 33%, p = 0.12), anti-PD-1 + anti-CTLA-4 (67% versus 56%, p = 0.34) and BRAF/MEK-inhibition (14% versus 23%, p = 0.06). Following anti-CTLA-4 treatment, no AYAs experienced a grade 3&ndash, 4 colitis, while 17% of the older adults did (p = 0.046). There was no difference in response to treatment between AYAs and older adults. The longer overall survival observed in AYAs (hazard ratio (HR) 0.7, 95% CI 0.6&ndash, 0.8) was explained by the increased cumulative incidence of non-melanoma related deaths in older adults (sub-distribution HR 2.8, 95% CI 1.5&ndash, 4.9), calculated by competing risk analysis. The results of our national cohort study show that baseline characteristics and mutational profiles differ between AYAs and older adults with advanced melanoma, leading to different treatment choices made in daily practice. Once treatment is initiated, AYAs and older adults show similar tumor responses and melanoma-specific survival.

Published
2020
Full Text
View/download PDF

138. Physical performance has a strong association with poor surgical outcome in older patients with colorectal cancer

Author

Souwer, Esteban TD, Moos, Shira I., van Rooden, Cornelis J., Bijlsma, Astrid Y., Bastiaannet, Esther, Steup, Willem H., Dekker, Jan Willem T., Fiocco, Marta, van den Bos, Frederiek, Portielje, Johanna EA, Souwer, Esteban TD, Moos, Shira I., van Rooden, Cornelis J., Bijlsma, Astrid Y., Bastiaannet, Esther, Steup, Willem H., Dekker, Jan Willem T., Fiocco, Marta, van den Bos, Frederiek, and Portielje, Johanna EA

Published
2020

139. Physical performance has a strong association with poor surgical outcome in older patients with colorectal cancer

Author

Unit Opleiding Aios, MS Geriatrie, Souwer, Esteban TD, Moos, Shira I., van Rooden, Cornelis J., Bijlsma, Astrid Y., Bastiaannet, Esther, Steup, Willem H., Dekker, Jan Willem T., Fiocco, Marta, van den Bos, Frederiek, Portielje, Johanna EA, Unit Opleiding Aios, MS Geriatrie, Souwer, Esteban TD, Moos, Shira I., van Rooden, Cornelis J., Bijlsma, Astrid Y., Bastiaannet, Esther, Steup, Willem H., Dekker, Jan Willem T., Fiocco, Marta, van den Bos, Frederiek, and Portielje, Johanna EA

Published
2020

140. Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Wetzels, Marjolein J A L, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, Dierselhuis, Miranda P, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Bastiaannet, Esther, Kapiteijn, Ellen, MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Wetzels, Marjolein J A L, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, Dierselhuis, Miranda P, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Bastiaannet, Esther, and Kapiteijn, Ellen

Published
2020

141. Improving outcomes for donation after circulatory death kidney transplantation: Science of the times

Author

MS Nefrologie, Circulatory Health, de Kok, Michèle J C, Schaapherder, Alexander F M, Alwayn, Ian P J, Bemelman, Frederike J, van de Wetering, Jacqueline, van Zuilen, Arjan D, Christiaans, Maarten H L, Baas, Marije C, Nurmohamed, Azam S, Berger, Stefan P, Bastiaannet, Esther, Ploeg, Rutger J, de Vries, Aiko P J, Lindeman, Jan H N, MS Nefrologie, Circulatory Health, de Kok, Michèle J C, Schaapherder, Alexander F M, Alwayn, Ian P J, Bemelman, Frederike J, van de Wetering, Jacqueline, van Zuilen, Arjan D, Christiaans, Maarten H L, Baas, Marije C, Nurmohamed, Azam S, Berger, Stefan P, Bastiaannet, Esther, Ploeg, Rutger J, de Vries, Aiko P J, and Lindeman, Jan H N

Published
2020

142. Abstract PS6-06: The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort

Author

Noordhoek, Iris, primary, Bastiaannet, Esther, additional, Lujinovic, Ersan, additional, Esserman, Laura, additional, Wesseling, Jelle, additional, Scholten, Astrid, additional, Schröder, Carolien P, additional, Elias, Sjoerd, additional, de Glas, Nienke A, additional, Kroep, Judith R, additional, Portielje, Johanneke EA, additional, Kleijn, Miranda, additional, and Liefers, Gerrit-Jan J, additional

Published
2021
Full Text
View/download PDF

143. Abstract PS6-08: The PORTRET-tool: A prediction tool for older patients with breast cancer that predicts recurrence, survival and other-cause mortality

Author

van der Plas-Krijgsman, Willeke, primary, Giardiello, Daniele, additional, Putter, Hein, additional, Steyerberg, Ewout W, additional, Bastiaannet, Esther, additional, Stiggelbout, Anne M, additional, Mooijaart, Simon P, additional, Portielje, Johanneke EA, additional, Liefers, Gerrit J, additional, and de Glas, Nienke A, additional

Published
2021
Full Text
View/download PDF

148. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care

Author

Huang, Lei, primary, Jansen, Lina, additional, Verhoeven, Rob H.A., additional, Ruurda, Jelle P., additional, Van Eycken, Liesbet, additional, De Schutter, Harlinde, additional, Johansson, Jan, additional, Lindblad, Mats, additional, Johannesen, Tom B., additional, Zadnik, Vesna, additional, Žagar, Tina, additional, Mägi, Margit, additional, Lagarde, Sjoerd M., additional, Bastiaannet, Esther, additional, van de Velde, Cornelis J.H., additional, Schrotz-King, Petra, additional, and Brenner, Hermann, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results